Canada's Essa Pharma Inc. launched an equity offering of 75 million units at 20 cents apiece, to raise gross proceeds of up to US$15 million.
Each unit will comprise one common share and an 18-month warrant to buy an additional stock for 22 cents.
Shares and warrants from the offering, which is expected to close by Dec. 21, will be listed on the TSX Venture Exchange and Nasdaq Capital Market.
Bloom Burton Securities Inc. is acting as sole Canada placement agent for the offering, with H.C. Wainwright & Co. serving as the sole U.S. placement agent.
The company granted Bloom Burton a 30-day overallotment option to buy up to an additional 15% of the units offered.
Essa Pharma plans to use net proceeds for the ongoing preclinical development of its Aniten compounds, payments on its outstanding debt, working capital and general corporate purposes.